FDA Grants Orphan Drug Designation for Tocagen's Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma

SAN DIEGO, Aug. 25, 2015 /PRNewswire/ -- Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. As previously announced, the investigational drug was granted FDA Fast Track designation for the treatment of recurrent high-grade glioma, which includes glioblastoma and anaplastic astrocytoma, and is poised to move into a pivotal clinical trial later this year.

Glioblastoma is the most common form of primary brain cancer, with over 10,000 people diagnosed every year in the United States. The disease is extremely aggressive; newly diagnosed patients have a five-year survival rate of less than 5 percent, and the tumor typically recurs following standard-of-care treatment. Median survival following recurrence is approximately eight months. Toca 511 & Toca FC is an investigational treatment that is designed to program cancer cells to convert the prodrug 5-FC into the anticancer drug 5-FU, killing tumor cells and leading to activation of the immune system via a combination of mechanisms.

"There's an extraordinary need for new treatment options for patients with this devastating disease," said Harry Gruber, M.D., chief executive officer of Tocagen. "We believe FDA's granting of both orphan drug and Fast Track designations to Toca 511 & Toca FC will enable us to more efficiently advance our program, which we hope will ultimately offer physicians and patients a new option in the fight against brain cancer."

The FDA's orphan drug designation is intended to encourage development of treatments for diseases that affect fewer than 200,000 individuals in the United States. Orphan drug designation qualifies the drug developer for various development incentives, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee for the condition for which the drug was designated. Orphan designation does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies.

About Toca 511 & Toca FC

Toca 511 & Toca FC is designed to program cancer cells to convert the prodrug 5-FC into the anticancer drug 5-FU, killing tumor cells and leading to activation of the immune system selectively against the tumor via a combination of mechanisms. Toca 511 is a retroviral replicating vector (RRV) that selectively delivers a gene for the enzyme cytosine deaminase to the tumor. Patients then take oral cycles of Toca FC, a novel formulation of an antifungal drug, which is converted within infected cancer cells into the FDA-approved anticancer drug, 5-fluorouracil (5 FU). As a result, in addition to direct 5-FU mediated killing the immune system is activated to recognize and kill cancer cells, leaving healthy cells unharmed. Immune activation locally in the tumor occurs through a combination of mechanisms that together break the barrier of immune tolerance and may lead to durable tumor response.

About Tocagen

Tocagen is a clinical-stage biopharmaceutical company pursuing the discovery, development and commercialization of products built upon a broadly applicable, highly tumor-selective immuno-oncology platform. The company's lead combination product, Toca 511 & Toca FC, is advancing into a pivotal Phase 2/3 study in 2015 for patients with recurrent glioblastoma or anaplastic astrocytoma. The FDA has granted Toca 511 & Toca FC both Fast Track and orphan drug designations. A study evaluating Toca 511 & Toca FC in five additional metastatic solid tumor indications is planned for 2016.

Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information about Tocagen or Toca 511 please visit www.tocagen.com or www.clinicaltrials.gov using the identifiers NCT01470794, NCT01156584, NCT01985256, or NCT02414165. For more information about Tocagen please visit www.tocagen.com or follow @Tocagen.

Media Contact:
Monica May 
Canale Communications
619-849-5383

SOURCE Tocagen Inc.

Related Links

http://www.tocagen.com